BMY vs PFE
Bristol-Myers Squibb · Pfizer
| BMY Bristol-Myers Squibb Healthcare | PFE Pfizer Healthcare | |
|---|---|---|
| Market | ||
| Price | $62.48 +1.78% | $30.52 +1.90% |
| Market cap | $127.6B | $174.0B |
| P/E (TTM) | 13.8 | 40.1 |
| Dividend yield | 4.58% | 5.38% |
| 52-week range | $43.20 – $68.64 | $23.62 – $30.67 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Bristol-Myers Squibb: The Forensic Case That The Patent Cliff Math Has Already Been Solved May 27, 2026 | Pfizer's Vyndaqel Patent Cliff Just Got Pushed To 2031 — The Market Hasn't Noticed Yet (P… Jun 14, 2026 |
| Latest earnings | ||
| Reported | Oct 29, 2026 | — |
| Revenue | $13.1 billion +7% YoY | — |
| EPS | $1.05 | — |
| Guidance | Guidance raised | — |
| Revenue growth, last 4 reports | +7% | — |
| Topics | ||
| Main topics | ||
| Company page · Earnings releases | Company page | |
Shared topics: Dividends Patent Cliff
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.